Companies › Glaukos
5 active drug programs in 9 registered trials: 4 Phase 4, 4 Phase 2, 1 Phase 3; Ophthalmology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Travoprost Prostanoid FP receptor agonist | PTGFR | Phase 4 | Glaucoma, Open-Angle; Glaucoma, Open-angle; Glaucoma; Open Angle Glaucoma | May 2027 |
| Riboflavin Ophthalmic Solutions Photosensitizer used in corneal cross-linking | – | Phase 4 | Keratoconus | Sep 2027 |
| GLK-321 | – | Phase 2 | Demodex Blepharitis | Nov 2026 |
| GLK-221 Ophthalmic Solution | – | Phase 2 | Keratoconus | Apr 2027 |
| lufepirsen connexin43 antisense oligonucleotide | GJA1 | Phase 2 | Persistent Corneal Epithelial Defect | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05966493 | lufepirsen | Phase 2 | Persistent Corneal Epithelial Defect | Ophthalmology | Dec 2025 |
| NCT07400965 | GLK-321 | Phase 2 | Demodex Blepharitis | Ophthalmology | Nov 2026 |
| NCT07400952 | GLK-221 Ophthalmic Solution | Phase 2 | Keratoconus | Ophthalmology | Apr 2027 |
| NCT06066645 | Travoprost | Phase 4 | Glaucoma, Open-Angle | Ophthalmology | May 2027 |
| NCT06848946 | Travoprost | Phase 4 | Glaucoma, Open-angle | Ophthalmology | Jun 2027 |
| NCT07629557 | Riboflavin Ophthalmic Solutions | Phase 4 | Keratoconus | Ophthalmology | Sep 2027 |
| NCT07075718 | Travoprost | Phase 2 | Glaucoma | Ophthalmology | Mar 2028 |
| NCT07495852 | Travoprost | Phase 3 | Glaucoma | Ophthalmology | Jun 2028 |
| NCT07228221 | Travoprost | Phase 4 | Open Angle Glaucoma | Ophthalmology | Aug 2031 |
Cash of $162m on 2026-09-30; operating cash flow positive
Press releases filed as 8-K in the last year:
SpyGlass Pharma YS Life Science Santen Pharmaceutical Triple Hair
YS Life Science Bausch & Lomb Santen Pharmaceutical Laboratoires Thea Taejoon Pharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.